Core Insights - The company is optimistic about expanding the reach of VYVGART in myasthenia gravis (MG), particularly in seronegative and ocular MG populations, with a PDUFA date set for May 10 [2][11] - The Phase 3 ADAPT OCULUS trial demonstrated statistically significant improvements in patients treated with VYVGART compared to placebo, indicating its effectiveness [3][4] - The company reported strong financial performance, achieving $4.2 billion in net sales for the year, marking its first annual operating profit [13][15] Clinical Development - The ADAPT OCULUS trial enrolled 141 patients and met its primary endpoint, showing a mean improvement of 4.04 points in the MG-II ocular score for VYVGART compared to 1.99 points for placebo [3][4] - The company plans to file a supplemental BLA with the FDA based on the trial results and aims to present broader data at an upcoming medical meeting [3][5] Commercial Performance - VYVGART has seen significant commercial momentum, with approximately 19,000 patients globally and a strong uptake of the prefilled syringe (PFS) for self-injection [7][8] - The company reported that VYVGART is the fastest-growing and most prescribed biologic in MG, with 70% of patients transitioning from oral therapies [8][9] Financial Results - The company achieved $1.3 billion in net sales for Q4 and $4.2 billion for the full year, representing a 90% year-over-year growth [13][15] - Operating expenses for Q4 totaled $955 million, with a gross margin consistent at 11% [14][15] - The company reported an operating profit of $367 million for Q4 and $1.1 billion for the full year, supported by favorable tax benefits and foreign exchange movements [15] Future Outlook - The company anticipates that it will take about two quarters post-approval to update payer policies and contracts for new label expansions [12] - Looking ahead to 2026, the company expects revenue growth to outpace operating expense growth, which will support expanding operating margins [16]